UNCY
Unicycive Therapeutics, Inc.
$5.73
+0.45 (+8.52%)
At close · Jul 2
Market Cap
$152.99M
Shares
26,700,027
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.73
Open$5.30
Day$5.10–5.79
52W$3.71–8.74
Avg vol 30d2.1M
Short int3.2M · 12.1% float · 3.7d
Short vol41%
Last earningsMay 12, 2026
DataJul 2021–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−9% below
−
Price vs 50-day avg
−23% below
◦
RSI (14)
41 · neutral
−
MACD trend
negative
◦
52-week position
40% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $7 › 200d $6 — 50d above 200d
+
Institutional flow
+46% holders QoQ · +19 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
12.12% of float · ▲ +14.1% MoM · 3.7 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
51 holders — near 1-yr high, broad support
Fundamentals
Fair
−
Revenue growth
−29% Y/Y
+
EPS growth
+70% Y/Y
−
Free cash flow
$-31.3M
+
Balance sheet
net cash $29.2M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Jul 19, 2026
Est · unconfirmed
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−9% below
Bearish
Price vs 50-day avg
−23% below
Bearish
RSI (14)
41 · neutral
Neutral
MACD trend
negative
Bearish
52-week position
40% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+46% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.12% of float · ▲ +14.1% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
51 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $6 · 40%
52-wk high $9
vs 200-day avg -9%
vs 50-day avg -23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
UNCY
this stock
Unicycive Therapeutics, Inc.
|
$152.99M | -0.7% | -29.0% | — | 12.1% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| UNCY | -30.2% | -20.4% | -6.4% | +22.2% | -0.7% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -31.6% | -19.2% | -14.4% | +22.4% | -9.9% |